US FDA Orders New Eye-Risk Warnings for Ozempic and Zepbound
The FDA said it is requiring new warnings after informing patients and healthcare providers of a potential increased risk of a serious eye condition associated with GLP-1 drugs used for weight loss and diabetes.
The US FDA on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs used for weight loss and diabetes.The US Food and Drug Administration said it is requiring GLP-1 drugs such as Eli Lilly's NYSE:LLY Mounjar…